Literature DB >> 1873221

Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity.

P M Green1, A J Montandon, R Ljung, D R Bentley, I M Nilsson, S Kling, F Giannelli.   

Abstract

Carrier and prenatal diagnosis based on the identification of the gene defect (direct diagnosis) increases the proportion of haemophilia B families that can be offered precise genetic counselling from the 50-60% attainable by DNA markers, to 100% and they also provide information on the molecular biology of the disease. We propose that in order to maximize the practical and scientific benefits of direct diagnosis the gene defect of complete (possibly national) populations of patients should be characterized and the information stored in appropriate confidential databases. We demonstrate the feasibility of such a strategy by characterizing the mutations of all the patients registered with the Malmö haemophilia centre. These patients (44 male and 1 female) are from 45 unrelated families and 24 (53%) have negative family history. The 25 patients with similar reduction of factor IX:C and factor IX:Ag (24 male + 1 female) have: two gross deletions, three frameshifts, four translation stops, six mutations expected to affect pre-mRNA splicing and 10 amino acid substitutions. The six patients with greater reduction of factor IX:C than factor IX:Ag and the seven with reduced IX:C and normal IX:Ag have only amino acid substitutions. Patients with inhibitors have: one complete deletion, one frameshift and three translation stops. One patient has both a translation stop and a functionally neutral amino acid substitution (His257----Tyr). Characterization of the factor IX mutation was successful in every case, usually entailed 4 person-days work, and has led to the identification of 12 amino acid residues essential for the factor IX structure and function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873221     DOI: 10.1111/j.1365-2141.1991.tb04453.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Screening for mutations in the gene encoding factor IX.

Authors:  L R Nielsen; M Schwartz; E Scheibel
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  A new strategy for the genetic counselling of diseases of marked mutational heterogeneity: haemophilia B as a model.

Authors:  F Giannelli; S Saad; A J Montandon; D R Bentley; P M Green
Journal:  J Med Genet       Date:  1992-09       Impact factor: 6.318

4.  Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992.

Authors:  F Giannelli; P M Green; K A High; S Sommer; D P Lillicrap; M Ludwig; K Olek; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

Review 5.  Key issues in inhibitor management in patients with haemophilia.

Authors:  Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

6.  Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B.

Authors:  P M Green; S Saad; C M Lewis; F Giannelli
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

7.  Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993.

Authors:  F Giannelli; P M Green; K A High; S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1993-07-01       Impact factor: 16.971

8.  Factor IX gene mutations causing haemophilia B: comparison of SSC screening versus systematic DNA sequencing and diagnostic applications.

Authors:  P Aguilar-Martinez; M C Romey; J F Schved; J C Gris; J Demaille; M Claustres
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

9.  Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Investigation of the German haemophilia B population and review of de novo mutations.

Authors:  O Knobloch; B Zoll; K Zerres; H H Brackmann; K Olek; M Ludwig
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

10.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

Authors:  Valder R Arruda; Hansell H Stedman; Timothy C Nichols; Mark E Haskins; Matthew Nicholson; Roland W Herzog; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.